Multiple Myeloma | Specialty

Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

January 8th 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

Dr. Martin on FDA Approval of Denosumab in Multiple Myeloma

January 5th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

FDA Approves Denosumab for Multiple Myeloma

January 5th 2018

The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

January 3rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

Dr. Usmani on the Gimema-MMY-3006 Study for Multiple Myeloma

December 21st 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

Daratumumab Regimen Maintains Favorable Performance in Relapsed/Refractory Myeloma

December 21st 2017

Progression-free survival remained superior over time in patients with relapsed/refractory multiple myeloma treated treated with combination therapy that included the anti-CD38 antibody daratumumab (Darzalex).

NICE Recommends Ixazomib for Multiple Myeloma Through CDF

December 20th 2017

The United Kingdom's National Institute for Health and Care Excellence has issued guidance recommending ixazomib in for patients with relapsed/refractory multiple myeloma.

Dr. Gasparetto on Selinexor and Daratumumab Combination in Multiple Myeloma

December 19th 2017

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

Selinexor Combo Highly Active in Relapsed/Refractory Myeloma

December 15th 2017

Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.

Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma

December 14th 2017

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.

New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma

December 14th 2017

The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.

BCMA Antibody-Drug Conjugate Reaches 60% Response in Myeloma

December 13th 2017

The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.

Elotuzumab/Lenalidomide Maintenance Deepens Responses After Transplant in Myeloma

December 13th 2017

Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.

Daratumumab Demonstrates Single-Agent Activity in Smoldering Myeloma

December 13th 2017

Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.

Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients

December 12th 2017

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr. Gasparetto on Results for Selinexor and Daratumumab in Relapsed/Refractory Multiple Myeloma

December 11th 2017

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab. Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.

Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma

December 11th 2017

A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

Case Study 2: Options for Biochemically Relapsed MM

December 8th 2017

Case Study 2: An Elderly Patient With Multiple Myeloma

December 8th 2017